GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (OTCPK:DSRLF) » Definitions » Research & Development

Diasorin SpA (Diasorin SpA) Research & Development : $98 Mil (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Diasorin SpA Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Diasorin SpA's Research & Development for the three months ended in Dec. 2023 was $25 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $98 Mil.

Diasorin SpA Research & Development Historical Data

The historical data trend for Diasorin SpA's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diasorin SpA Research & Development Chart

Diasorin SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.28 61.80 79.20 102.65 99.18

Diasorin SpA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.38 24.95 24.92 23.48 25.02

Diasorin SpA Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA  (OTCPK:DSRLF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Diasorin SpA Research & Development Related Terms

Thank you for viewing the detailed overview of Diasorin SpA's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Diasorin SpA (Diasorin SpA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (OTCPK:DSRLF) » Definitions » Research & Development
Comparable Companies
HKSE:08070 HKSE:01379 HKSE:01273 HKSE:01591 HKSE:00380 HKSE:01629 HKSE:00544 HKSE:01758 HKSE:00379 HKSE:01720 TSE:2309 TMO DHR IQV IDXX XSWX:LONN A MTD ICLR ILMN
Traded in Other Exchanges
DIA:Italy 0GZX:UK 34D:Germany
Address
Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Website
https://www.diasoringroup.com
Diasorin SpA is a biotechnology company engaged in developing, producing, and marketing reagent kits for laboratory diagnostics around the world. The business has focused on the immunodiagnostic market, molecular diagnostics, and Life Science sector. The company has a presence in Italy, Europe, North America, and the Rest of the world, where the majority of its revenue is from North America followed by Italy.